Amgen's Repatha cholesterol drug significantly reduces the risk of first cardiac events by 25% in at-risk patients.
On Oct. 10, the FDA classified the recalled prescription medication as a Class II recall. The risk classification from the federal agency indicates that the recalled medications could cause "temporary ...
A record-breaking 4,432 scientific abstracts accepted at the American Heart Association’s meeting here adorned posters, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback